Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 100.4% in August

Vivos Therapeutics, Inc. (NASDAQ:VVOS) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 2,503,479 shares, an increase of 100.4% from the August 15th total of 1,249,260 shares. Currently, 18.4% of the company’s shares are sold short. Based on an average trading volume of 49,532,777 shares, the days-to-cover ratio is presently 0.1 days.

Vivos Therapeutics Price Performance

Shares of VVOS stock traded down $0.00 during trading hours on Wednesday, hitting $0.16. The stock had a trading volume of 786,788 shares, compared to its average volume of 4,664,396. The stock’s 50 day moving average is $0.32 and its 200 day moving average is $0.69. Vivos Therapeutics has a twelve month low of $0.16 and a twelve month high of $3.70. The firm has a market capitalization of $2.25 million, a PE ratio of -0.08 and a beta of 6.04.

Vivos Therapeutics (NASDAQ:VVOS) last issued its earnings results on Friday, August 14th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.10. Vivos Therapeutics had a negative net margin of 122.00% and a negative return on equity of 2,325.64%. The business had revenue of $5.15 million for the quarter, compared to the consensus estimate of $5.63 million. As a group, equities analysts predict that Vivos Therapeutics will post -1.54 earnings per share for the current year.

Institutional Trading of Vivos Therapeutics

An institutional investor recently bought a new stake in Vivos Therapeutics stock. Sequoia Financial Advisors LLC purchased a new position in shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 24,000 shares of the company’s stock, valued at approximately $28,000. Sequoia Financial Advisors LLC owned approximately 0.18% of Vivos Therapeutics at the end of the most recent reporting period. Institutional investors own 26.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. Ascendiant Capital Markets raised their price objective on Vivos Therapeutics from $3.00 to $3.10 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $2.80.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.